News

MaaT Pharma Achieves Recruitment Milestone for aGvHD Trial

MaaT Pharma Achieves Recruitment Milestone for aGvHD Trial

MaaT Pharma Achieves Recruitment Milestone for aGvHD Trial

MaaT Pharma has recently announced a key accomplishment in its Phase 3 trial for MaaT013, designed to treat steroid-refractory acute Graft-versus-Host Disease (aGvHD). This achievement is notable as recruitment for the study has reached its goal, marking a significant step for the company and its commitment to cancer therapy.

Understanding the ARES Trial

The ARES trial is a pivotal Phase 3 multicenter study that aims to evaluate the safety and efficacy of MaaT013 for patients suffering from GI-aGvHD. As part of this study, the company initially planned to enroll up to 75 patients, accounting for potential dropouts, but impressively enrolled 66 patients. This number is crucial for achieving statistically significant results about the efficacy of the drug.

What is MaaT013?

MaaT013 is an innovative Microbiome Ecosystem Therapy™ developed to assist in immune modulation for cancer patients. It represents a significant advancement in the treatment of aGvHD, a serious condition that can occur following a stem cell transplant. By restoring gut microbiota balance, MaaT013 aims to minimize complications associated with traditional immunosuppressive treatments.

Current Context of Acute Graft-versus-Host Disease

Acute Graft-versus-Host Disease is a severe reaction that occurs when transplanted immune cells attack the host's tissues, particularly after stem cell or bone marrow transplants. This reaction often leads to inflammation and severe symptoms, including life-threatening diarrhea. For patients unresponsive to steroids, alternative therapies are critical, and this is where MaaT013 aims to make a significant impact.

Milestones Ahead for MaaT013

MaaT Pharma has outlined several forthcoming milestones for the MaaT013 program. Early in December, the company plans to host discussions featuring key opinion leaders to share updated data from its Early Access Program. Then, in January, the topline results regarding the primary endpoint will be evaluated, providing insights into the overall response rate in patients.

Company's Vision and Commitment

MaaT Pharma's dedication to advancing treatments for blood cancer patients is evident. Hervé Affagard, the CEO, expressed his enthusiasm about completing recruitment for the trial, which aligns with the mission to enhance patient outcomes. The company has been at the forefront of microbiome-driven therapies, and with ongoing research, it holds the potential to pioneer groundbreaking solutions in the oncology space.

Company Overview

Founded in 2014 and positioned in Lyon, France, MaaT Pharma is a late-stage clinical biotechnology company. It focuses on developing groundbreaking therapies that utilize the gut microbiome to improve cancer treatment efficacy. MaaT013 is part of a broader strategy to modify immune response, which could fundamentally change the treatment landscape for patients facing severe complications from aGvHD.

Frequently Asked Questions

What is the significance of the ARES trial for MaaT Pharma?

The ARES trial represents a crucial step in evaluating the efficacy and safety of MaaT013, marking a milestone in the company's mission to treat patients with acute Graft-versus-Host Disease.

How does MaaT013 work?

MaaT013 works by restoring the balance of gut microbiota, which plays a role in modulating the immune system and reducing the severity of aGvHD.

What are the future steps for MaaT Pharma regarding MaaT013?

MaaT Pharma plans to host discussions with key opinion leaders to present updated data from the Early Access Program, followed by the release of topline results in January regarding GI Overall Response Rate.

What does acute Graft-versus-Host Disease entail?

Acute Graft-versus-Host Disease occurs when transplanted immune cells attack the recipient's body, leading to various severe symptoms and complications, particularly affecting the gastrointestinal tract.

Why is the development of microbiome therapies critical in oncology?

The development of microbiome therapies is vital as they may offer new ways to enhance immune response and provide safer and more effective treatment options for cancer patients, potentially reducing side effects from traditional therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 640

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Partnership Boosts Clinical Trials with AI Insights

Updated Category News Views 138

Transforming Clinical Trials Through AI Collaboration In a groundbreaking announcement, NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an innovative leader in artificial intelligence, has entered into a significant partnership with Pentara Corporation, a trusted name in the pharmaceutical data analytics sector. This collaboration aims to...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 414

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Minerals Technologies Enhances Pet Care Operations for Future Growth

Updated Category News Views 95

Minerals Technologies' Strategic Expansion in Pet Care Sector Minerals Technologies Inc. (NYSE: MTX) is making substantial strides to expand its operations in the pet care sector, particularly focusing on its SIVO™ brand of cat litter. This global leader in specialty minerals is undergoing transformative upgrades in its facilities across various countries, responding to...

Continue Reading
Insight into Latest Trading Activities of Treatt plc

Updated Category News Views 194

Key Information about Treatt plc Trading FORM 8.5 (EPT/RI) Public Disclosure by an Exempt Principal Trader in Client-Serving Capacity Rule 8.5 of the Takeover Code (the "Code") Essential Details (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree related to this form: Treatt plc (c) Connection of Exempt Principal Trader t

Continue Reading
Breeze Holdings Forms Strategic Alliance with YD Biopharma

Updated Category News Views 87

Breeze Holdings and YD Biopharma Unite Breeze Holdings Acquisition Corp. is thrilled to share an important milestone in its journey. The company has reached a definitive agreement to merge with YD Biopharma Limited. This isn't just any business deal; it marks a significant move toward advancements in cancer prevention and diagnostics. Discovering YD Biopharma's Purpose YD...

Continue Reading